Clinical trials on colorectal cancer (CRC) involving anti-EGFR antibodies, cetuximab and panitumumab, convincingly demonstrated that these drugs do not render benefit in tumors carrying KRAS or NRAS mutation. This evidence concerns the gene NRAS and colorectal carcinoma.